ENTRY       D10335                      Drug
NAME        Alirocumab (USAN);
            Praluent (TN)
PRODUCT     PRALUENT (Regeneron Pharmaceuticals)
            PRALUENT (Sanofi US Corporation)
            PRALUENT (Sanofi-Aventis U.S. LLC)
FORMULA     C6472H9996N1736O2032S42
EXACT_MASS  145892.049
MOL_WEIGHT  145981.7606
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFN NYAMNWVRQA PGKGLDWVST ISGSGGTTNY
            ADSVKGRFII SRDSSKHTLY LQMNSLRAED TAVYYCAKDS NWGNFDLWGR GTLVTVSSAS
            TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
            YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
            VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
            KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
            GNVFSCSVMH EALHNHYTQK SLSLSPG
            (Light chain)
            DIVMTQSPDS LAVSLGERAT INCKSSQSVL YRSNNRNFLG WYQQKPGQPPNLLIYWASTR
            ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYTT PYTFGQGTKL EIKRTVAAPS
            VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS
            LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
            (Disulfide bridge: H22-H96, H145-H201, H221-L-220, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'220, H'262-H'322, H'368-H'426, L23-L94, L140-L200, L'23-L'94, L'140-L'200)
  TYPE      Peptide
CLASS       Hypolipidemic agent
             DG01946  Hypolipidemic agent
              DG03128  Anti-PCSK9 antibody and siRNA
REMARK      ATC code: C10AX14
            Product: D10335<US>
EFFICACY    Antihyperlipidemic, Anti-PCSK9 antibody
  DISEASE   Mmyocardial infarction [DS:H01730]
            Primary hyperlipidemia [DS:H01635]
            Heterozygous familial hypercholesterolemia [DS:H00155]
  TYPE      Monoclonal antibody
COMMENT     Treatment of hypercholesterolemia
TARGET      PCSK9 [HSA:255738] [KO:K13050]
  PATHWAY   hsa04979(255738)  Cholesterol metabolism
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             C CARDIOVASCULAR SYSTEM
              C10 LIPID MODIFYING AGENTS
               C10A LIPID MODIFYING AGENTS, PLAIN
                C10AX Other lipid modifying agents
                 C10AX14 Alirocumab
                  D10335  Alirocumab (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Cardiovascular Agents
              Dyslipidemics, PCSK9 Inhibitor
               Alirocumab
                D10335  Alirocumab (USAN)
            Drug groups [BR:br08330]
             Hypolipidemic agent
              DG01946  Hypolipidemic agent
               DG03128  Anti-PCSK9 antibody and siRNA
                D10335  Alirocumab
            Drug classes [BR:br08332]
             Cardiovascular agent
              DG01946  Hypolipidemic agent
               D10335  Alirocumab
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Serine peptidases
                PCSK9
                 D10335  Alirocumab (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10335
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10335
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10335
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10335
DBLINKS     CAS: 1245916-14-6
            PubChem: 172232429
///
